Elsevier

Biochemical Pharmacology

Volume 167, September 2019, Pages 163-172
Biochemical Pharmacology

Review
Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer

https://doi.org/10.1016/j.bcp.2019.06.004Get rights and content

Abstract

Poly(ADP-ribosyl)ation is a unique post-translational modification of proteins. The metabolism of poly(ADP-ribose) (PAR) is tightly regulated mainly by poly(ADP-ribose) polymerases (PARP) and poly(ADP-ribose) glycohydrolase (PARG). Accumulating evidence has suggested the biological functions of PAR metabolism in control of many cellular processes, such as cell proliferation, differentiation and death by remodeling chromatin structure and regulation of DNA transaction, including DNA repair, replication, recombination and transcription. However, the physiological roles of the catabolism of PAR catalyzed by PARG remain less understood than those of PAR synthesis by PARP. Noteworthy biochemical studies have revealed the importance of PAR catabolic pathway generating nuclear ATP via the coordinated actions of PARG and ADP-ribose pyrophosphorylase (ADPRPPL) for the driving of DNA repair and the maintenance of DNA replication apparatus while repairing DNA damage. Furthermore, genetic studies have shown the value of PARG as a therapeutic molecular target for PAR-mediated diseases, such as cancer, inflammation and many pathological conditions. In this review, we present the current knowledge of de-poly(ADP-ribosyl)ation catalyzed by PARG focusing on its role in DNA repair, replication and apoptosis. Furthermore, the induction of apoptosis code of DNA replication catastrophe by synthetic lethality of PARG inhibition and the recent progresses regarding the development of small molecule PARG inhibitors and their therapeutic potentials in cancer chemotherapy are highlighted in this review.

Introduction

Poly(ADP-ribosyl)ation (PARylation) is a dynamic post-translational modification of proteins catalyzed by members of the PARP family of enzymes and multiples of the PARG splice-variant isoforms in mammalian cells [1], [2], [3], [4], [5], [6], [7], [8], [9]. This unique protein modification uses NAD+ as a substrate. Studies over the past two decades have led to an expansion of our knowledge of the biological functions of PAR metabolism in many molecular, cellular and pathological processes. Our concept regarding the physiological significances of NAD+-(ADP-ribose)n metabolism is the fundamental regulation of DNA transaction (DNA repair, replication, recombination and transcription) and genome maintenance, and thereby the control of three fundamental cellular processes, cell proliferation, differentiation and apoptosis (Fig. 1) [8]. Furthermore, it plays important roles in aging, inflammation, cancer and other diseases in relation to energy metabolism.

PARylation of chromosomal proteins has been well studied in DNA repair processes [7], [8], [9], [10], [11], [12]. In DNA damage repair, PARP is recruited to the sites of DNA lesions and activated to polymerize ADP-ribose moiety of NAD+ to γ-carboxyl groups of the glutamic acid residues of acceptor proteins (Figs. 2, 3; Reaction a). The PAR acts as an important signal for recruitment of repair factors to the damaged sites allowing DNA repair. Before DNA repair can start, PAR needs to be degraded by PARG. In 1989, the novel catabolic pathway of PAR for the generation of ATP in nuclei has been discovered [13] (Fig. 3): ADP-ribose liberated from PAR by PARG (Reaction b) is converted to ATP and ribose-5-phosphate (R-5-P) by the action of ADP-ribose pyrophosphorylase (ADPRPPL) (Reaction c) near the sites of DNA damage. This nuclear ATP works for the driving-force of the DNA repair processes, such as DNA polymerization and ligation, and the maintenance of DNA replication apparatus during DNA repair [8], [13], [14], [15], [16], [17], [18]. These findings have provided new insights into the physiological function of PAR turnover.

Recently, PARP inhibitor olaparib was firstly approved for cancer treatment targeting advanced ovarian cancer associated with defective BRCA1/2 genes, in which PARP inhibitors act to promote synthetic lethality [19], [20], [21], [22], [23]. Accordingly, PARP inhibitors could kill homologous recombination repair (HRR) deficient cancer cells. Furthermore, PARP inhibitors have shown promise of good treatment for stroke, heart disease and inflammation [24], [25]. Thus, PARylation by PARP has received considerable attention. On the other hand, the study of de-PARylation catalyzed by PARG has been still limited and the biological significance remains less understood [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37]. However, in recent years, structural and genetic studies have been performed to gain an insight into the biological functions of PARG [38], [39], [40], [41], [42], [43], [44], [45]. Furthermore, PARG inhibitors are developing to facilitate the studies of the pathological roles of PARG and its therapeutic potential in various diseases, especially in cancer [46], [47], [48], [49], [50], [51], [52], [53], [54], [55].

Given the key roles of PARG in numerous physiological and pathological states, the potential benefit of targeting PARG for therapeutic purposes is considerably high [8], [9]. This review will present the recent progresses regarding the physiological functions of PAR catabolism catalyzed by PARG and the current knowledge of the synthetic lethality of PARG inhibitors and the development of novel PARG inhibitors for cancer chemotherapy.

Section snippets

Poly(ADP-ribose) is primarily for NAD+ reservoir

Poly(ADP-ribose) [PAR, (ADP-R)n] was discovered over 50 years ago [4], [5], [6]. The new field of biological science is still more expanded and now becomes important in medical science. PAR is synthesized from NAD+ substrate by the action of PARP family of enzymes, which are activated by DNA breaks having 3′-OH [1], [2], [3], [4], [5], [6]. This polymer has a unique structure of repeating ADP-ribose units derived from NAD+, with its size ranging from a few to approximately 200 ADP-ribose

Roles of poly(ADP-ribose) glycohydrolase in cell death

PARG was found to be encoded by a single gene in mammalian cells [69]. The Parg gene undergoes alternative splicing, which results in multiple PARG isoforms that have been suggested to be located in different organelles [70]. During apoptosis, like PARP-1 [71], PARG is cleaved into two C-terminal fragments (74 and 85 kDa) by caspase-3 [72]. Recently, the absence or knockdown of PARG has been shown to lead to decrease caspase activities [50]. Furthermore, ADP-ribose generated from PAR by PARG

Biological significance of poly(ADP-ribose) catabolism in DNA repair

DNA damaging events per day in cells in usual states are estimated to be approximately 10,000 sites [83]. With the apparent high turnover rate of NAD+ [14], [15], [84], [85], if PAR were responsible for most (85–90%) NAD+ consumption, PAR should relatively undergo rapid turnover. This allows precise regulation of acceptor protein’s functions and adequate control of cellular responses. Given the multitude of NAD+ consuming reactions, such as mono(ADP-ribosyl)ation, cyclic ADP-ribose formation

A new strategy for cancer chemotherapy targeting poly(ADP-ribose) glycohydrolase

Cancer cells are known to show an increased rate of DNA damage and defecting one or more DNA repair mechanisms [86]. So, inhibitors targeting the ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related protein (ATR) kinases involved in DNA double strand break repair are currently undergoing clinical evaluation [86], [87], [88]. Interestingly, PARP inhibitors have shown to be synthetic lethal in homologous recombination repair (HRR) deficient cancers, such as these mutant

Development of poly(ADP-ribose) glycohydrolase inhibitors

The dynamic metabolism of PAR suggests a closely coordinated mode of actions of PARP and PARG. However, the biological and physiological roles of PARG are still not well elucidated as compared with those of PARP. It has been reported that the degradation of PAR by PARG leads to remodeling chromatin structure during various DNA transaction, such as DNA repair, replication, recombination and transcription [14], [18], [41], [42], [63], [64], [91], [92], [93], [94], [95], [96], [97], [98], [99].

Concluding perspectives

The past two decades have brought a number of discoveries that have changed our understanding of the physiological significances of NAD+-poly(ADP-ribose) metabolism [8], [9]. Biochemical and cell biological studies on PAR turnover have provided fundamental evidence of the important roles of PARP and PARG in DNA repair, replication and cell death or survival. In cancer chemotherapy, PARP inhibitors, olaparib, niraparib and rucaparib, are already being used clinically in specific tumors,

Declaration of Competing Interest

None.

Acknowledgements

We thank Dr. Takashi Sugimura (National Cancer Center Research Institute), Dr. Masanao Miwa (Nagahama Institute of Bio-Science and Technology), Dr. Mitsuko Masutani (National Cancer Center Research Institute and Nagasaki University), Dr. Yoshiyuki Kanai (Choju Medical Institute, Fukushimura Hospital) and Dr. Akira Sato (Tokyo University of Science) for helpful discussions. We also thank the laboratory colleagues, Daisuke Ashizawa, Ryo Ota, Sachie Kanamaki, Yuka Kato, Mariko Kamioka, Shota Oba,

References (119)

  • M. Miwa et al.

    Purification and properties of glycohydrolase from calf thymus splitting ribose-ribose linkages of poly(adenosine diphosphate ribose)

    J. Biol. Chem.

    (1974)
  • S. Tanuma et al.

    Purification and properties of an (ADP-ribose)n glycohydrolase from guinea pig liver nuclei

    J. Biol. Chem.

    (1986)
  • S. Tanuma et al.

    Identification of two activities of (ADP-ribose)n glycohydrolase in HeLa S3 cells

    Biochem. Biophys. Res. Commun.

    (1986)
  • K. Hatakeyama et al.

    Purification and characterization of poly(ADP-ribose) glycohydrolase. Different modes of action on large and small poly(ADP-ribose)

    J. Biol. Chem.

    (1986)
  • H. Abe et al.

    Properties of poly(ADP-ribose) glycohydrolase purified from pig testis nuclei

    Arch. Biochem. Biophys.

    (1996)
  • E. Winstall et al.

    Poly(ADP-ribose) glycohydrolase is present and active in mammalian cells as a 110-kDa protein

    Exp. Cell Res.

    (1999)
  • K.M. Frizzell et al.

    Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells

    J. Biol. Chem.

    (2009)
  • S. Cuzzocrea et al.

    Role of poly(ADP-ribose) glycohydrolase (PARG) in shock, ischemia and reperfusion

    Pharmacol. Res.

    (2005)
  • M. Miwa et al.

    The branching and linear portions of poly(adenosine diphosphate ribose) have the same alpha(1 leads to 2) ribose-ribose linkage

    J. Biol. Chem.

    (1981)
  • V. Schreiber et al.

    Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1

    J. Biol. Chem.

    (2002)
  • S. Tanuma et al.

    ADP-ribosylation of nonhistone high mobility group proteins in intact cells

    J. Biol. Chem.

    (1983)
  • S. Tanuma et al.

    ADP-ribosylation of chromosomal proteins and mouse mammary tumor virus gene expression. Glucocorticoids rapidly decrease endogenous ADP-ribosylation of nonhistone high mobility group 14 and 17 proteins

    J. Biol. Chem.

    (1983)
  • L.O. Burzio et al.

    ADP ribosylation of rat liver nucleosomal core histones

    J. Biol. Chem.

    (1979)
  • W. Lin et al.

    Isolation and characterization of the cDNA encoding bovine poly(ADP-ribose) glycohydrolase

    J. Biol. Chem.

    (1997)
  • M.L. Meyer-Ficca et al.

    Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments

    Exp. Cell Res.

    (2004)
  • E.B. Affar et al.

    Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis

    J. Biol. Chem.

    (2001)
  • X. Feng et al.

    Silencing of Apoptosis-Inducing factor and poly(ADP-ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy

    Mol. Cancer

    (2012)
  • M.J. O'Connor

    Targeting the DNA damage response in cancer

    Mol. Cell

    (2015)
  • A.M. Weber et al.

    ATM and ATR as therapeutic targets in cancer

    Pharmacol. Ther.

    (2015)
  • P. Gravells et al.

    Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase

    DNA Repair

    (2017)
  • Y.J. Tsai et al.

    Mouse mammary tumor virus gene expression is suppressed by oligomeric ellagitannins, novel inhibitors of poly(ADP-ribose) glycohydrolase

    J. Biol. Chem.

    (1992)
  • K. Aoki et al.

    A macrocircular ellagitannin, oenothein B, suppresses mouse mammary tumor gene expression via inhibition of poly(ADP-ribose) glycohydrolase

    Biochem. Biophys. Res. Commun.

    (1995)
  • S. Tanuma et al.

    Poly(ADP-ribosyl)ation of chromosomal proteins in the HeLa S3 cell cycle

    J. Biol. Chem.

    (1982)
  • S. Tanuma et al.

    Poly(ADP-ribose) glycohydrolase is present in metaphase chromosomes of HeLa S3 cells

    Biochem. Biophys. Res. Commun.

    (1982)
  • A. Tulin et al.

    Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases

    Curr. Top. Dev. Biol.

    (2003)
  • T. Sugimura et al.

    Poly(ADP-ribose) and cancer research

    Carcinogenesis

    (1983)
  • K. Ueda et al.

    ADP-ribosylation

    Annu. Rev. Biochem.

    (1985)
  • F.R. Althaus et al.

    ADP-ribosylation of proteins. Enzymology and biological significance

    Mol. Biol., Biochem., Biophys.

    (1987)
  • H. Hilz et al.

    Poly(ADP-ribose) and ADP-ribosylation of proteins

    Rev. Physiol., Biochem. Pharmacol.

    (1976)
  • O. Hayaishi et al.

    Poly(ADP-ribose) and ADP-ribosylation of proteins

    Annu. Rev. Biochem.

    (1977)
  • M. Miwa et al.

    PolyADP-ribosylation and cancer

    Cancer Sci.

    (2007)
  • S. Tanuma et al.

    New insights into the roles of NAD+-Poly(ADP-ribose) metabolism and poly(ADP-ribose) glycohydrolase

    Curr. Protein Pept. Sci.

    (2016)
  • M. Miwa et al.

    Poly(ADP-ribose): structure, physicochemical properties and quantification in vivo, with special reference to poly(ADP-ribose) binding protein modules

    Curr. Protein Pept. Sci.

    (2016)
  • J.M. de Murcia et al.

    Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

    PNAS

    (1997)
  • H. Maruta et al.

    The involvement of ATP produced via (ADP-Ribose)n in the maintenance of DNA replication apparatus during DNA repair

    Biol. Pharm. Bull.

    (2007)
  • H. Maruta et al.

    [Role of poly(ADP-ribosyl)ation in cell death], Seikagaku

    J. Jpn. Biochem. Soc.

    (2005)
  • H.E. Bryant et al.

    Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

    Nature

    (2005)
  • H. Farmer et al.

    Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Nature

    (2005)
  • N.C. Turner et al.

    A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

    EMBO J.

    (2008)
  • A. Sonnenblick et al.

    An update on PARP inhibitors–moving to the adjuvant setting

    Nat. Rev. Clin. Oncol.

    (2015)
  • Cited by (11)

    • The search for inhibitors of macrodomains for targeting the readers and erasers of mono-ADP-ribosylation

      2021, Drug Discovery Today
      Citation Excerpt :

      Thus, the development of inhibitors that target macrodomains is vital for the elucidation of their cellular functions and of MARylation itself. The structure and function of macrodomains as well as the development of PARylation-related macrodomain inhibitors have been already discussed in several reviews.30–37 Therefore, here, we mainly focus on the development of inhibitors of macrodomains specifically involved in MARylation, including the mammalian macrodomains 2/3 of PARP14 and MacroD1, and the viral macrodomains of the Chikungunya virus (CHIKV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Fig. 1a).

    • Structural insights into the active site of poly(ADP-ribose) glycohydrolase using docking modes of 6-hydroxy-3H-xanthen-3-one derivative inhibitors

      2020, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      The dynamic metabolism of poly(ADP-ribose) (PAR) suggests a closely coordinating mode of actions of poly(ADP-ribose) polymerase (PARP) family and poly(ADP-ribose) glycohydrolase (PARG) splice variants1–6.

    View all citing articles on Scopus
    View full text